- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05934786
Rehabilitation of Cognition and Psychosocial Well-being in Epilepsy (ReCaPABLE)
Rehabilitation of Cognition and Psychosocial Well-being - A Better Life With Epilepsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the current project is to conduct a randomized waitlist-controlled trial of an original CoRE program, assess its overall efficacity and determine factors associated with a better response to this intervention.
Work schedule Objective 1: To prepare for the study before patient enrolment (2023-04-01 to 2023-12-31, 9 months) Task 1.1. Acquisition of ethical approval according to local regulations, preparation of infrastructure (e.g., reservation of dedicated examination rooms), and personnel. The required infrastructure for clinical examination and evaluation (e.g., electroencephalography, examination rooms) will be available within the clinical center of Vilnius University Hospital Santaros Klinikos while the infrastructure for the conduct of the intervention will be available at the Counseling and training center of the Faculty of Philosophy at Vilnius University. Vilnius University will also provide access to the data management software "MIDAS" and the statistical package for data analysis (SPSS).
Task 1.2. Development of experimental testing material and intervention. This subtask will be accomplished through meetings between investigators in clinical neurology and psychology. Experimental testing material will be developed after conducting a literature review and discussing the tests' feasibility (e.g., duration, mode of application, result analysis).
Task 1.3. Preparation of the study protocol for publication (expected acceptance before patient enrolment) Objective 2: To start patient enrolment and baseline evaluation (2024-01-01 to 2024-02-31, 2 months) and proceed with continuous enrolment, evaluation, intervention, and follow-up (2024-03-01 to 2024-11-30, 9 months).
Task 2.1. Patient recruitment and baseline evaluation Patients will be recruited by neurologists and explained the purpose and workflow of the trial.
The sample size was calculated for a between-group interaction of a two-way repeated measures analysis of variance (ANOVA) with f=0.40, α=0.05, β=0.95, two groups (early and late intervention), three measurement points, 0.5 correlation between repeated measures and no adjustment for non-sphericity. The resulting sample size of n=58 (G*Power 3.1.9.7) was increased by 20% to n=70 to account for dropouts and corresponded well to the mean sample size and attrition rates in previous trials (Joplin et al., 2018).
Inclusion criteria:
Active epilepsy (medication for epilepsy and/or had at least one seizure in the past year) Adults (>17 years) Lithuanian speaker No intellectual disability
Exclusion criteria:
Sensory or motor deficit preventing task completion Epilepsy surgery planned during the project Active non-paroxysmal comorbid disorder of the central nervous system (e.g., neurodegeneration, multiple sclerosis) Active psychiatric disorder during the past year Psychoactive substance use (except social alcohol, tobacco, and caffeine use)
Components of the baseline evaluation:
Demographic and socioeconomic characteristics (case report form) Clinical characteristics (e.g., seizure frequency, type and duration of epilepsy, medication use, comorbidities, previous exposure to psychological counseling), case report form.
Epilepsy re-evaluation by the neurologist (including electroencephalography) Questionnaire data (scales used): quality of life (QOLIE-31-P), anxiety (GAD-7), depression (NDDI-E), suicidality (Columbia Suicide Severity Rating Scale), metacognition (MCQ-30), Jacoby's 3-item Stigma Scale, antiseizure drug adverse effects (LAEP), the Short Form (36) Health Survey, subjective evaluation of cognitive functions (ad hoc Likert scales 0 to 10).
Objective neuropsychological assessment, up to one hour per examination (indicated examples may be substituted by equivalent tests):
Reaction speed (e.g., Trail Making Tests A and B) Working memory (e.g., Digit Span Test) Verbal fluency (e.g., categorical, phonemic naming) Short-term and long-term memory: verbal (short story or word list) and visuospatial (complex figure) at three delays (e.g., immediate, 30 min, and 4 weeks) to test for accelerated forgetting.
Experimental memory tasks with high everyday significance (e.g., map learning, appointment memory, close autobiographical memory) Task 2.2. The intervention (2024-03-01 to 2024-11-31 (early intervention group) and 2025-06-01 to 2026-03-31 (late intervention group)) Patient randomization will be done using dedicated software (e.g., https://www.randomizer.org/). The investigators performing questionnaire-based and neuropsychological assessment will be blinded from the status of the patient.
The intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework. It will be developed after group meetings and all psychologists will be trained by a leading specialist to ensure standardization.
Task 2.3. End of patient recruitment and intervention, last follow-up investigations (2024-12-01 to 2025-03-31, 4 months) Objective 3: To conduct data analysis and disseminate the results (2025-04-01 to 2026-03-31, 12 months) Task 3.1 Data analysis, drafting, and editing of the final report, publication, and presentation of the study results (2025-04-01 to 2026-03-31, 12 months).
The efficacy of the intervention will be defined as a significant improvement in one of the primary outcomes (quality of life or verbal memory), tested with a repeated measure between factors AN(C)OVA. Dynamic changes of other outcome measures will be tested respectively. The association between demographic and clinical variables with study endpoints will be conducted by means of linear and ordinal regression modeling. Open-access publishing of the study results will be sought.
Intervention is simultaneously done for the late intervention group, which is treated as a waitlist control during data analysis (see Task 2.2).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Active epilepsy (medication for epilepsy and/or had at least one seizure in the past year)
- Adults (>17 years)
- Lithuanian speaker
- No intellectual disability
Exclusion Criteria:
- Sensory or motor deficit preventing task completion
- Epilepsy surgery planned during the project
- Active non-paroxysmal comorbid disorder of the central nervous system (e.g.,
- neurodegeneration, multiple sclerosis)
- Active psychiatric disorder during the past year
- Psychoactive substance use (except social alcohol, tobacco and caffeine use)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Early intervention group
The intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months (8 weeks) per patient).
|
Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
|
|
Active Comparator: late intervention group
For 8 weeks this group will receive the usual treatment, then, after repeated cognitive evaluation, will receive the same intervention: six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
|
Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life index
Time Frame: Immediately before intervention and after.
|
QOLIE-31-P will be used before and after interventions.
The efficacy of the intervention will be defined as a change from baseline value immediately before intervention at 8 weeks immediately after intervention
|
Immediately before intervention and after.
|
|
Delayed verbal recall
Time Frame: Immediately before intervention, after 30 minutes and after 4 weeks immediately after intervention
|
The short story and word list will be used immediately before the intervention, repeated after 30 minutes and immediately after intervention after 4 weeks.
The efficacy of the intervention will be defined as a change from baseline value at 30 minutes and a change from baseline value at 4 weeks
|
Immediately before intervention, after 30 minutes and after 4 weeks immediately after intervention
|
|
Delayed visual recall
Time Frame: Immediately before intervention, at 30 minutes and immediately after intervention at 4 weeks
|
The complex figure test will be used immediately before the intervention, repeated after 30 minutes and immediately after intervention after 4 weeks.
The efficacy of the intervention will be defined as a change from baseline value at 30 minutes and a change from baseline value at 4 weeks.
|
Immediately before intervention, at 30 minutes and immediately after intervention at 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mood
Time Frame: Immediately before and two times (immediately after the intervention and 8 weeks later).
|
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) for evaluation of depression will be used.
The change from baseline value at 8 and 16 weeks will be assessed
|
Immediately before and two times (immediately after the intervention and 8 weeks later).
|
|
Anxiety
Time Frame: Immediately before and after intervention.
|
Generalized anxiety disorder (GAD) inventory for evaluation of anxiety will be used two times - before and after interventions (after 8 and 16 weeks).
The change from baseline value at 8 and 16 weeks will be assessed
|
Immediately before and after intervention.
|
|
Stigma
Time Frame: Immediately before and after intervention.
|
Jacoby's 3-item Stigma Scale will be used two times - before and after interventions (after 8 and 16 weeks).
The change from baseline value at 8 and 16 weeks will be assessed.
|
Immediately before and after intervention.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Behavior
- Personal Satisfaction
- Epilepsy
- Psychological Well-Being
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Neurological Rehabilitation
- Cognitive Training
Other Study ID Numbers
- ReCaP-ABLE-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustNot yet recruitingEpilepsy Intractable | Epilepsy in Children
-
Massachusetts General HospitalBoston University; National Institute of Neurological Disorders and Stroke...CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of ChildhoodUnited States
-
University Hospital, LilleCompletedFocal Epilepsy | Epilepsy IntractableFrance
Clinical Trials on Cognitive rehabilitation
-
University of North Carolina, Chapel HillUnited States Department of Defense; Foundation of Hope, North CarolinaCompletedTraumatic Brain Injury | Posttraumatic Stress DisorderUnited States
-
Ege UniversityUnknown
-
Istituti Clinici Scientifici Maugeri SpARecruitingCognitive Impairment | Dementia | Vascular Dementia | Dementia, Mixed | Comorbidities and Coexisting ConditionsItaly
-
I.R.C.C.S. Fondazione Santa LuciaCompleted
-
Vanderbilt UniversityVanderbilt University Medical CenterCompletedBrain Injuries | Dementia | Muscle Disorders | MyopathiesUnited States
-
Samsung Medical CenterCompletedMild Cognitive ImpairmentKorea, Republic of
-
Sunnybrook Health Sciences CentreFondazione Italiana Sclerosi Multipla; University of Alabama at Birmingham; University... and other collaboratorsCompletedCognitive Impairment | Multiple Sclerosis, Primary ProgressiveCanada
-
Samsung Medical CenterCompleted
-
University Hospital, BordeauxMerck Serono International SA; ARSEP foundationCompletedMultiple Sclerosis | Cognitive RehabilitationFrance
-
Badalona Serveis AssistencialsCompletedCognitive Dysfunction | Aging | Mild Cognitive ImpairmentSpain